April 14

Biopharma tariffs becoming more than a threat

Impact of tariffs on supplies of semiconductor tough to calculate

April 11

Novartis boosting US manufacturing with $23B investment

April 10

Dems petition White House to ensure drug supply chains stay intact

Loss of experience at US FDA raises concerns as impact felt

April 9

Many US tariffs paused, pharma warned, EU put on notice

US-China trade war accelerates with biotech in the crosshairs

April 8

Experts cite deadly consequences of PEPFAR funding disruption

Markets lose ground as US Senate meets on Trump tariffs

Europe’s med-tech companies assessing implications of tariffs

Many med-tech company supply chains protected from tariffs

April 7

US court says no to NIH indirect rate cut, another suit filed

April 3

Impact of Trump tariffs on med tech proving difficult to anticipate

Biopharma exempt from US reciprocal tariffs, but not untouched 

Tariffs pressure industry markets; uncertainty remains

Asia in firing line of Trump tariffs, but health care escapes largely unscathed

With ‘wholesale assault’ on research, bipartisan alarm at institutional failure

April 2

Trump cuts are 'gutting' research grants, 'destabilizing' science

US to impose ‘kind reciprocal’ tariffs on country-by-country basis

Kennedy called to Senate HELP hearing on HHS reorg

April 1

Where’s the ‘radical transparency’ Kennedy promised?

March 31

Marks’ departure intensifies regulatory uncertainty at US FDA

March 28

Australia looks to Asia as Trump administration threatens funding

Medidata CEO says digital therapeutics, drugs future of patient treatment

March 27

BIO survey points to ‘damaging impacts’ of Trump tariffs

HHS to cut staffing levels by 20,000 under efficiency initiative

March 26

Senate votes in Makary, Bhattacharya at FDA and NIH

March 25

Oz hits Wyden’s wall of skepticism in Senate CMS post hearing

March 24

CDC’s ACIP meeting rescheduled

March 21

EU seeking talented scientists amid US funding woes

March 19

Trump halves the FTC, firing Democratic commissioners

March 18

WHO looking to fill funding gap left by the US

March 14

Oz promises AI, innovation, lower drug prices if confirmed to lead CMS

Lost in trans-lation? Trump’s mouse charge doesn’t click

March 13

US CDC nomination withdrawn, reforms in the works

Just one more vote to go for FDA, NIH nominees

March 10, 2025

As tariffs threaten US imports of APIs, companies reshore manufacturing

CDC briefing: Trump cuts disrupt disease surveillance, deplete talent

March 6, 2025

US FDA nominee HELPed on the way to confirmation

March 5, 2025

Bhattacharya shares his vision for US NIH

March 4, 2025

Trump’s EOs keep coming as US agencies await new leadership

March 3, 2025

NIH changes set industry up for workforce, ideas drought

Pallone, DeGette push back on FDA, other HHS dismissals

Feb, 25, 2025

New admin toes the Biden line on Rx price negotiations

Feb. 24, 2025

US lawmakers tell Kennedy: No more ‘indiscriminate’ terminations

Feb. 21, 2025

Amid the chaos, focus on innovation, says Stifel’s Opler

Raft of FDA job cuts may slow med-tech approvals

Feb. 20, 2025

Still waiting for the dust to settle at US FDA, throughout HHS

Feb. 19, 2025

Pharmaceuticals named as tariff target, starting at 25% 

Feb. 18, 2025

Thousands of US HHS staff terminated in name of efficiency 

AAAS 2025: Former NIH head Bertagnolli sounds warning on funding cuts

Feb. 14, 2025 

Trump administration an existential threat to science, warns AAAS chief

Feb. 13, 2025

NIH funding plans threaten to derail ‘synergistic partnership’

Uncertainty builds amid Kennedy confirmation, Trump’s orders

Feb. 11, 2025  

Court orders full stop to US NIH slashing of indirect rates

Infographic: Indirect costs of NIH grants

BIO CEO 2025: Navigating from policy to innovation to patients

BIO CEO 2025: Cognition CEO debates policy while advancing CT-1812

Feb. 10, 2025

BIO CEO 2025: A ‘nice upswing’ in VC rounds, but uncertainty looms

Scientists warn NIH cost-cutting will impair research

Feb. 7, 2025

Trump’s executive orders stacking up, along with challenges

Trump administration presents a mixed picture for med tech

Admin's actions toward science agencies 'not a measured reappraisal'

Mixed reactions from Asia on biotech implications of Trump 2.0

Speculations rise on US tariff impact on global pharma industry